KR100528720B1 - 중금속 제거용 특수 영양식품 - Google Patents
중금속 제거용 특수 영양식품 Download PDFInfo
- Publication number
- KR100528720B1 KR100528720B1 KR10-2002-0051416A KR20020051416A KR100528720B1 KR 100528720 B1 KR100528720 B1 KR 100528720B1 KR 20020051416 A KR20020051416 A KR 20020051416A KR 100528720 B1 KR100528720 B1 KR 100528720B1
- Authority
- KR
- South Korea
- Prior art keywords
- heavy metals
- weight
- special nutritional
- nutritional food
- adhd
- Prior art date
Links
- 229910001385 heavy metal Inorganic materials 0.000 title claims abstract description 43
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims description 3
- 238000009825 accumulation Methods 0.000 title description 9
- 230000002401 inhibitory effect Effects 0.000 title description 2
- 235000013402 health food Nutrition 0.000 title 1
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 16
- 239000011707 mineral Substances 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 229940088594 vitamin Drugs 0.000 claims abstract description 9
- 229930003231 vitamin Natural products 0.000 claims abstract description 9
- 235000013343 vitamin Nutrition 0.000 claims abstract description 9
- 239000011782 vitamin Substances 0.000 claims abstract description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 24
- 239000011701 zinc Substances 0.000 claims description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 15
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 15
- 229910052725 zinc Inorganic materials 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 14
- 239000011669 selenium Substances 0.000 claims description 14
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229960003180 glutathione Drugs 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- 229910052711 selenium Inorganic materials 0.000 claims description 12
- 108010024636 Glutathione Proteins 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 9
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229940011671 vitamin b6 Drugs 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 235000008160 pyridoxine Nutrition 0.000 claims description 6
- 239000011677 pyridoxine Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 229960001295 tocopherol Drugs 0.000 claims description 4
- 235000010384 tocopherol Nutrition 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 239000011133 lead Substances 0.000 abstract description 28
- 230000006735 deficit Effects 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 208000013403 hyperactivity Diseases 0.000 abstract description 17
- 239000011651 chromium Substances 0.000 abstract description 12
- 231100000419 toxicity Toxicity 0.000 abstract description 11
- 230000001988 toxicity Effects 0.000 abstract description 11
- 229910052793 cadmium Inorganic materials 0.000 abstract description 10
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 abstract description 10
- 229910052787 antimony Inorganic materials 0.000 abstract description 6
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 abstract description 6
- 229910052785 arsenic Inorganic materials 0.000 abstract description 6
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052804 chromium Inorganic materials 0.000 abstract description 5
- 229910052782 aluminium Inorganic materials 0.000 abstract description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003472 neutralizing effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 22
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 22
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 22
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 16
- 102000003792 Metallothionein Human genes 0.000 description 16
- 108090000157 Metallothionein Proteins 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 235000010755 mineral Nutrition 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 102000006587 Glutathione peroxidase Human genes 0.000 description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- -1 zinc or copper Chemical compound 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 231100000640 hair analysis Toxicity 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-IGMARMGPSA-N Calcium-40 Chemical compound [40Ca] OYPRJOBELJOOCE-IGMARMGPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000030668 Zinc disease Diseases 0.000 description 1
- DCOLOVHTJKNUOI-UHFFFAOYSA-J [OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++] Chemical compound [OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++] DCOLOVHTJKNUOI-UHFFFAOYSA-J 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- WSUTUEIGSOWBJO-UHFFFAOYSA-N dizinc oxygen(2-) Chemical compound [O-2].[O-2].[Zn+2].[Zn+2] WSUTUEIGSOWBJO-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000003947 neutron activation analysis Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940003613 zinc oxide 10 mg Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/76—Yeasts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pediatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
정상 ADHD | |
비소(As) | < |
안티몬(Sb) | < |
납(Pb) | < |
비스무스(Bi) | < |
마그네슘(Mg) | > |
칼륨(K) | < |
칼슘(Ca) | > |
아연(Zn) | > |
셀레늄(Ce) | > |
바나듐(V) | < |
니켈(Ni) | > |
스트론튬(Sr) | > |
몰리브덴(Mo) | < |
주석(Sn) | < |
[참고문헌]1) 학급 아이들의 모발내 납축적과 주의력결핍된 행동과의 관계 [Archives of Environmental Health, 1996, Vol. 51 (No. 3)]2) 주의력결핍-과잉행동장애(ADHD)에서의 아연결핍 [Biol Psychiatry 1996;40;1308-1310]3) 학습장에 아이들 모발의 원소함량[Science, Vol. 198 p 204 - 206]4) Brain Zinc와 아연이 부족한 음식을 먹은 쥐의 일시적 학습능력 손상과의 관계 [Brain Research 859 (2000) 352-357]5) serum의 free fatty acids와 zinc, 그리고 ADHD와의 관계 [J. Child Psychol, Vol 37. No 2 pp 225-227. 1996]6) 주의력결핍/과잉행동장애 대한 Fatty acid의 본질인 아연과 Amphetamine 치료 [Journal of Child and Adolescent Psychopharmacology, Vol 10. No 2, 2000, pp 111-117]7) 저농도의 납 폭로와 아이들의 IQ간의 관계 [Environmental Research 65, 42-55(1994)] |
분류 | 실시예 1 | 실시예 2 | |
글루타치온 함유 건조 효모 | 1500 ㎎ | 1500 ㎎ | |
비타민 E 초산 에스테르분말 | 25 ㎎ | 25 ㎎ | |
염산 피리독신 | 17 ㎎ | 17 ㎎ | |
아스코르빈산 | 85 ㎎ | 85 ㎎ | |
칼슘 | 해조칼슘 | 40 ㎎ | - |
유청칼슘 | - | 40mg | |
마그네슘 | 수산화마그네슘 | 20 mg | 20mg |
아연 | 산화아연 | 10 ㎎ | 10mg |
셀레늄 함유 건조 효모 | 79 ㎎ | 79 ㎎ | |
부형제 | 오렌지맛분말 | 1280 ㎎ | 1280 ㎎ |
오렌지향분말 | 10 ㎎ | 10 ㎎ | |
카르복실메칠셀룰로오스 나트륨 | 7 ㎎ | 7 ㎎ | |
락토바실루스분말 | 500 ㎎ | 500 ㎎ | |
스테아린산 마그네슘 | 6 ㎎ | 6 ㎎ | |
상기 실시예는 3579 mg/포로 구성 |
ADHD 환자(실시예 투약 전) | 평 균(ppm) | ||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | ||
성별 | 남 | 남 | 여 | 남 | 여 | 남 | 남 | 남 | |
나이 | 7 | 8 | 9 | 11 | 10 | 10 | 10 | 10 | |
Al | 6.85 | 2.62 | 15.20 | 9.95 | 18.50 | 12.98 | 8.80 | 11.90 | 10.85 |
As | 0.24 | 0.15 | 0.04 | 0.06 | 0.07 | 0.09 | 0.12 | 0.14 | 0.11 |
Cd | 0.20 | 0.02 | 0.12 | 0.05 | 0.05 | 0.40 | 0.20 | 0.37 | 0.18 |
Sb | 0.08 | 0.02 | 0.03 | 0.02 | 1.81 | 0.04 | 0.03 | 0.04 | 0.26 |
Ba | 0.54 | 0.08 | 1.18 | 1.09 | 2.66 | 0.51 | 0.62 | 0.90 | 0.95 |
Pb | 3.00 | 0.37 | 4.35 | 1.39 | 0.67 | 9.62 | 2.41 | 6.64 | 3.56 |
Na | 1.1 | 6.1 | 112.1 | 10.6 | 4.7 | 2.8 | 14.1 | 6.8 | 7.3 |
Mg | 12.6 | 28.8 | 44.8 | 85.8 | 46.6 | 12.3 | 11.1 | 37.2 | 34.9 |
P | 158 | 231 | 132 | 131 | 125 | 157 | 153 | 147 | 154 |
K | 4.45 | 11.39 | 18.20 | 13.80 | 3.76 | 4.55 | 19.90 | 25.00 | 12.63 |
Ca | 175 | 308 | 488 | 509 | 878 | 251 | 303 | 373 | 411 |
Cr | 0.434 | 0.425 | 0.314 | 0.313 | 0.284 | 0.495 | 0.518 | 0.386 | 0.40 |
Mn | 0.422 | 0.083 | 0.505 | 0.44 | 0.267 | 0.335 | 0.301 | 0.619 | 0.37 |
Fe | 16.5 | 8.21 | 19.4 | 15.6 | 19.3 | 13.6 | 13.6 | 15.3 | 15.2 |
Cu | 7.49 | 7.84 | 13.6 | 12.4 | 19.8 | 9.35 | 9.59 | 17 | 12.13 |
Zn | 71 | 139 | 156 | 177 | 176 | 166 | 157 | 176 | 151 |
Se | 0.719 | 0.893 | 0.702 | 0.675 | 0.692 | 0.651 | 0.548 | 0.696 | 0.70 |
ADHD 환자(실시예 투약 후) | 평 균(ppm) | ||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | ||
성별 | 남 | 남 | 여 | 남 | 여 | 남 | 남 | 남 | |
나이 | 7 | 8 | 9 | 11 | 10 | 10 | 10 | 10 | |
Al | 2.62 | 1.92 | 11.20 | 4.80 | 11.60 | 5.22 | 4.88 | 9.08 | 6.42 |
As | 0.15 | 0.07 | 0.05 | 0.06 | 0.05 | 0.08 | 0.13 | 0.10 | 0.09 |
Cd | 0.02 | 0.01 | 0.04 | 0.02 | 0.07 | 0.05 | 0.15 | 0.09 | 0.05 |
Sb | 0.02 | 0.01 | 0.02 | 0.01 | 0.07 | 0.02 | 0.03 | 0.02 | 0.02 |
Ba | 0.08 | 0.06 | 0.70 | 0.42 | 2.49 | 0.25 | 0.33 | 0.35 | 0.58 |
Pb | 0.37 | 0.18 | 1.54 | 0.25 | 0.43 | 3.11 | 1.75 | 2.00 | 1.20 |
Na | 6.1 | 3.2 | 5.7 | 3.5 | 3.7 | 5.8 | 5.2 | 3.5 | 4.6 |
Mg | 28.8 | 35.6 | 40.1 | 32.1 | 65.4 | 18.7 | 22.0 | 24.9 | 33.5 |
P | 231 | 199 | 158 | 158 | 146 | 180 | 184 | 183 | 180 |
K | 11.39 | 4.81 | 10.21 | 6.90 | 3.71 | 12.16 | 12.18 | 12.93 | 9.29 |
Ca | 308 | 438 | 566 | 444 | 1166 | 289 | 352 | 424 | 498 |
Cr | 0.425 | 0.498 | 0.33 | 0.331 | 0.314 | 0.345 | 0.357 | 0.419 | 0.38 |
Mn | 0.083 | 0.076 | 0.267 | 0.182 | 0.239 | 0.144 | 0.244 | 0.523 | 0.22 |
Fe | 8.21 | 7.44 | 11.6 | 7.86 | 7.96 | 8.85 | 8.02 | 11 | 8.9 |
Cu | 7.84 | 7.86 | 12.3 | 10.2 | 60.3 | 9.32 | 10 | 19.4 | 17.15 |
Zn | 139 | 155 | 188 | 188 | 178 | 155 | 153 | 164 | 165 |
Se | 0.893 | 0.879 | 1.18 | 1.07 | 0.902 | 0.81 | 1.16 | 1.6 | 1.06 |
Claims (2)
- 아미노산류로서 글루타치온(Glutathione, GSH) 함유 효모 1500 mg,비타민류로서 토코페롤 25 mg, 피리독신 17 mg, 및 아스코르빈산 85 mg,미네랄류로서 칼슘 40 mg, 마그네슘 20 mg, 및 아연 10 mg, 그리고셀레늄 함유 건조 효모 79 mg이상기한 중량비로 함유된 것임을 특징으로 하는 중금속 제거용 특수 영양식품.
- 제 1 항에 있어서, 상기 특수 영양식품은 정제, 캅셀제, 산제, 과립제, 세립제, 환제, 액제, 시럽제 및 현탁화제 중에서 선택된 제형인 것을 특징으로 하는 중금속 제거용 특수 영양식품.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0051416A KR100528720B1 (ko) | 2002-08-29 | 2002-08-29 | 중금속 제거용 특수 영양식품 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0051416A KR100528720B1 (ko) | 2002-08-29 | 2002-08-29 | 중금속 제거용 특수 영양식품 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040019710A KR20040019710A (ko) | 2004-03-06 |
KR100528720B1 true KR100528720B1 (ko) | 2005-11-15 |
Family
ID=37324469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0051416A KR100528720B1 (ko) | 2002-08-29 | 2002-08-29 | 중금속 제거용 특수 영양식품 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100528720B1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100785375B1 (ko) * | 2006-12-29 | 2007-12-18 | 주식회사 과학기술분석센타 | 중금속중독 예방을 위한 사료. |
KR20180058251A (ko) * | 2016-11-23 | 2018-06-01 | 충남태안영농조합법인 | 굼벵이를 이용한 체내 미네랄 균형 유지, 중금속의 생체 내 흡수 방지 및 체외 배출을 위한 기능성 식품 조성물 |
KR20180133242A (ko) * | 2018-12-05 | 2018-12-13 | 충남태안영농조합법인 | 굼벵이를 이용한 체내 미네랄 균형 유지, 중금속의 생체 내 흡수 방지 및 체외 배출을 위한 기능성 식품 조성물 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2377007C1 (ru) * | 2008-06-23 | 2009-12-27 | Открытое Акционерное Общество "Инвестиционная Финансовая Группа "Гленик-М" | Средство для лечения и профилактики онкологических заболеваний и способ применения этого средства (варианты) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950016537A (ko) * | 1993-12-14 | 1995-07-20 | 최인호, 로버트.엘.오디 | 항산화제제 조성물 및 유지식품의 산화방지방법 |
KR970068894A (ko) * | 1996-04-24 | 1997-11-17 | 강대일 · 정영숙 | 미네랄, 생약재엑기스 및 아미노산이 함유된 건강식품조성물 |
KR20010071467A (ko) * | 1999-04-16 | 2001-07-28 | 피에트로 폴라 | 글루타티온의 흡수 증가와 그것의 효과를 상승시키는데유용한 카르니틴과 글루타티온 함유 조성물 |
KR20040005407A (ko) * | 2002-07-10 | 2004-01-16 | 이명석 | 노화 방지 효과가 있는 조성물 |
-
2002
- 2002-08-29 KR KR10-2002-0051416A patent/KR100528720B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950016537A (ko) * | 1993-12-14 | 1995-07-20 | 최인호, 로버트.엘.오디 | 항산화제제 조성물 및 유지식품의 산화방지방법 |
KR970068894A (ko) * | 1996-04-24 | 1997-11-17 | 강대일 · 정영숙 | 미네랄, 생약재엑기스 및 아미노산이 함유된 건강식품조성물 |
KR20010071467A (ko) * | 1999-04-16 | 2001-07-28 | 피에트로 폴라 | 글루타티온의 흡수 증가와 그것의 효과를 상승시키는데유용한 카르니틴과 글루타티온 함유 조성물 |
KR20040005407A (ko) * | 2002-07-10 | 2004-01-16 | 이명석 | 노화 방지 효과가 있는 조성물 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100785375B1 (ko) * | 2006-12-29 | 2007-12-18 | 주식회사 과학기술분석센타 | 중금속중독 예방을 위한 사료. |
KR20180058251A (ko) * | 2016-11-23 | 2018-06-01 | 충남태안영농조합법인 | 굼벵이를 이용한 체내 미네랄 균형 유지, 중금속의 생체 내 흡수 방지 및 체외 배출을 위한 기능성 식품 조성물 |
KR20180133242A (ko) * | 2018-12-05 | 2018-12-13 | 충남태안영농조합법인 | 굼벵이를 이용한 체내 미네랄 균형 유지, 중금속의 생체 내 흡수 방지 및 체외 배출을 위한 기능성 식품 조성물 |
KR102114633B1 (ko) * | 2018-12-05 | 2020-05-26 | 에이치엠오건강드림영농조합법인 | 굼벵이와 구기자를 이용한 카드뮴 배출을 위한 기호성이 향상된 기능성 식품 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20040019710A (ko) | 2004-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Graziano et al. | Dose-response study of oral 2, 3-dimercaptosuccinic acid in children with elevated blood lead concentrations | |
Taylor et al. | Trace element medicine and chelation therapy | |
US5932624A (en) | Vitamin supplement composition | |
WO2003003981A2 (en) | Compositions for improving mental performance | |
RU2309751C1 (ru) | Способ лечения нарушений минерального обмена при артрите, или остеохондрозе, или рахите, или артрозе, или остеопорозе | |
KR100528720B1 (ko) | 중금속 제거용 특수 영양식품 | |
CN101601681A (zh) | 用于降低血糖和血脂的药物组合物 | |
Prasad | Discovery of human zinc deficiency and marginal deficiency of zinc | |
RU2377009C1 (ru) | Биологически активная добавка, способствующая снижению массы тела | |
Williams et al. | Trace elements medicine and chelation therapy | |
CN101269103B (zh) | 用于优生优育预防出生缺陷和改善记忆的药物组合物 | |
CN101375896B (zh) | 用于预防出生缺陷与改善记忆的药物组合物 | |
RU2091043C1 (ru) | Растительно-минеральная пищевая добавка | |
RU2274453C1 (ru) | Фармацевтическая композиция для стабилизации гемостаза и купирования патологических процессов в организме | |
CN114073739A (zh) | 瘟疫发生的原因、治疗瘟疫药物的制备方法和使用方法 | |
Akshatha et al. | An approach to Panduhara Rasa Dravyas as per Rasa Ratna Samucchaya-A review | |
CN101396397B (zh) | 用于预防出生缺陷及改善记忆的药物组合物 | |
CN101375913B (zh) | 用于预防出生缺陷和改善记忆的药物组合物 | |
CN101375906B (zh) | 用于预防出生缺陷与改善记忆的药物组合物 | |
CN101396410A (zh) | 用于优生优育预防出生缺陷并能改善记忆的药物组合物 | |
WO1998008524A1 (en) | Multimineral products useful in achieving autonomic balance | |
CN101342211A (zh) | 用于预防出生缺陷及改善记忆的药物组合物 | |
CN101306051A (zh) | 用于预防出生缺陷和改善记忆的药物组合物 | |
CN101371863A (zh) | 用于预防出生缺陷和改善记忆的药物组合物 | |
CN101327251A (zh) | 用于预防出生缺陷及改善记忆的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121105 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131111 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141105 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20151105 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161107 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20171106 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20191105 Year of fee payment: 15 |